United Therapeutics and a Major Milestone in Lung Transplants
United Therapeutics Corporation (NASDAQ: UTHR), a public benefit corporation, alongside its subsidiary Lung Bioengineering Inc. (LBE), proudly announces the remarkable achievement of completing the 500th lung transplant utilizing their innovative centralized ex vivo lung perfusion (EVLP) service. This significant milestone reflects a decade-long commitment to enhancing the viability of donated lungs and improving transplant outcomes.
Significance of the 500th Lung Transplant
The groundbreaking 500th lung transplant was successfully performed at a renowned healthcare institution. This achievement not only underscores the success of LBE’s centralized EVLP service but also highlights an extensive history of evaluating over 800 donated lungs through this advanced technology since its inception.
The Process of Ex Vivo Lung Perfusion
Understanding the intricacies of lung transplantation provides valuable insights into why EVLP is such an essential innovation in this field. Lungs are among the most delicate organs and are often impacted by injuries and infections, making them challenging to transplant successfully. Historically, only a fraction of donor lungs meet the traditional criteria for transplantation. EVLP enables the evaluation of donated lungs outside the human body, allowing for critical data collection and assessment of lung viability in real-time.
How EVLP Works
The process involves flushing, ventilating, and warming the donor lungs to match normal body temperatures while simultaneously transmitting pertinent data to healthcare professionals. With EVLP, the medical teams can determine which lungs may be suitable for transplant that otherwise would have been considered non-viable.
Commitment to Progress and Innovation
United Therapeutics is dedicated to evolving the landscape of organ transplantation through continued innovation. The achievements of LBE and its clinically trained specialists result from collaborative efforts with transplant centers and organ procurement organizations. With more than 30 skilled professionals, LBE operates in strategically located facilities, ensuring that they can provide necessary services across North America.
Expanding the Reach
LBE has successfully received lungs from various donor hospitals, ranging in location from the far reaches of Alaska to Puerto Rico. Following EVLP, these lungs have been accepted for transplant in medical centers from Miami to Toronto, demonstrating the far-reaching implications of their efforts.
Future Aspirations
As United Therapeutics looks forward, the vision remains clear: to eradicate the waitlist for organ transplants. Plans are in motion to expand their centralized EVLP centers beyond their current locations in Maryland and Florida, striving to meet the growing need for transplantable organs.
Innovations Beyond Lung Transplants
LBE's centralized EVLP service is part of a broader initiative at United Therapeutics aimed at developing alternatives to traditional organ transplantation. This includes pioneering work in xenotransplantation, regenerative medicine, bio-artificial organ substitutes, and advanced bioprinting technologies.
About Lung Bioengineering
Lung Bioengineering Inc. (LBE) stands as the first and only full-service ex-vivo lung perfusion center in the United States. Established as a subsidiary of United Therapeutics in 2014, LBE’s objective is now clearer than ever—to revolutionize how donated organs are utilized, thereby minimizing the burdens associated with the donation process and increasing the overall organ utilization rates.
Company Vision
United Therapeutics is a trailblazer in the pharmaceutical and biotech realm, engaging in creative and unconventional methods to cater to the unmet needs of patients. Their public benefit purpose drives them to innovate continuously, primarily focused on expanding the availability of essential transplant organs.
Frequently Asked Questions
What is the significance of the 500th lung transplant?
The 500th lung transplant signifies a major achievement in using advanced perfusion technology, enhancing organ viability and patient outcomes.
How does the ex vivo lung perfusion process work?
EVLP evaluates donated lungs outside the body, allowing medical teams to assess viability through real-time data collection before transplantation.
What innovations is United Therapeutics pursuing?
United Therapeutics is advancing multiple technologies, including xenotransplantation, bio-artificial organs, regenerative medicine, and 3D bioprinting.
Where are Lung Bioengineering's facilities located?
Lung Bioengineering operates in Silver Spring, Maryland, and Jacksonville, Florida, with plans for further expansions.
What is United Therapeutics' core mission?
United Therapeutics aims to create a future where no one waits for a lifesaving transplant through persistent innovation and public benefit initiatives.
